Abstracts tagged "liver disease and randomized trials"

Abstract Number: 2357 • 2019 ACR/ARP Annual Meeting
Methotrexate Liver Toxicity in a Large Randomized Controlled Trial
Daniel Solomon¹, Nina Paynter ², Anna Rutherford ², Robert Glynn ³, Jean MacFadyen ⁴, Fengxin Lu ⁴, Chang Xu ⁴, Elizabeth Karlson ⁴ and Paul Ridker ², ¹Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Harvard Medical School - Boston, MA, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Liver test abnormalities are known to predict liver pathology in patients using methotrexate (MTX). Monitoring guidelines for MTX suggest frequent assessment of liver tests…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Abstracts tagged "liver disease and randomized trials"

Methotrexate Liver Toxicity in a Large Randomized Controlled Trial